159 filings
Page 3 of 8
8-K
k81yp9taq4ll0d9h3
3 Jun 22
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
z38foi614 vnz5y9r7
5 May 22
Denali Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
4:03pm
DEFA14A
7vnyg kdddo9lsrks
19 Apr 22
Additional proxy soliciting materials
4:03pm
8-K
41i6ee1hl0rpn qfv7
16 Mar 22
Denali Therapeutics Appoints Alexander Schuth as Chief Operating and Financial
4:20pm
8-K
763y4rtj8ul
28 Feb 22
Entry into a Material Definitive Agreement
5:27pm
S-3ASR
xitfovk 6mq6ls3bkx
28 Feb 22
Automatic shelf registration
5:26pm
S-8
bxuyoo8q36 7u
28 Feb 22
Registration of securities for employees
4:22pm
8-K
6rgus0tx nt4kylse
28 Feb 22
Denali Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
4:04pm
8-K
rz0 8ntebltd7z2ybc
14 Feb 22
Regulation FD Disclosure
6:29am
8-K
fc55i4 v5y7s1ad
10 Feb 22
Other Events
9:01am
8-K
l5k882ro vhscngcvsxa
7 Feb 22
Denali Therapeutics Announces Appointment of Erik Harris to Board of Directors
4:03pm
8-K
3zrwuled9q5
10 Jan 22
Denali Therapeutics Announces Progression and Expansion of Broad Therapeutic Portfolio for Neurodegeneration and Expected Key Milestones in 2022
9:06am
8-K
birpuim
17 Nov 21
Regulation FD Disclosure
9:03am
8-K
j7sqoa9i 813
4 Nov 21
Denali Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
4:04pm
8-K
t3d 538ict545ug
4 Aug 21
Denali Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights
4:03pm